RGTLF (Argent Biopharma) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


What is Argent Biopharma Forward Dividend Yield %?

Argent Biopharma RGTLF Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. The stock has 8 warning signs investors should review. Among 504 Drug Manufacturers companies, Argent Biopharma ranks worse than 198412.5% on this metric.

As of today (2026-06-25), the Forward Annual Dividend Yield of Argent Biopharma is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of Argent Biopharma is 0.00%.

RGTLF's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.095
* Ranked among companies with meaningful Forward Dividend Yield % only.

Argent Biopharma's Dividends per Share for the six months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Argent Biopharma  (OTCPK:RGTLF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Argent Biopharma Forward Dividend Yield % Related Terms

RGTLF vs ZTS, UTHR: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Forward Dividend Yield % falls into.


Argent Biopharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Argent Biopharma (RGTLF) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #999999 out of 504 companies in the Drug Manufacturers industry.
Is Argent Biopharma's Forward Dividend Yield % too high?
Argent Biopharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Argent Biopharma ranks #999999 out of 504 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #999999 out of 504 companies for Forward Dividend Yield %. This places Argent Biopharma in the lower half of its industry. The industry median Forward Dividend Yield % is 2.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.10, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.